- Home
- ACRS vs NIU Comparison
ACRS vs NIU Comparison
Compare ACRS & NIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- NIU
- Stock Information
- Founded
- ACRS 2012
- NIU 2014
- Country
- ACRS United States
- NIU China
- Employees
- ACRS N/A
- NIU N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- NIU Auto Manufacturing
- Sector
- ACRS Health Care
- NIU Consumer Discretionary
- Exchange
- ACRS Nasdaq
- NIU Nasdaq
- Market Cap
- ACRS 230.8M
- NIU 275.6M
- IPO Year
- ACRS 2015
- NIU 2018
- Fundamental
- Price
- ACRS $2.85
- NIU $3.61
- Analyst Decision
- ACRS Strong Buy
- NIU
- Analyst Count
- ACRS 5
- NIU 0
- Target Price
- ACRS $9.75
- NIU N/A
- AVG Volume (30 Days)
- ACRS 1.4M
- NIU 552.9K
- Earning Date
- ACRS 11-06-2025
- NIU 11-17-2025
- Dividend Yield
- ACRS N/A
- NIU N/A
- EPS Growth
- ACRS N/A
- NIU N/A
- EPS
- ACRS N/A
- NIU N/A
- Revenue
- ACRS $15,742,000.00
- NIU $625,182,280.00
- Revenue This Year
- ACRS N/A
- NIU $42.51
- Revenue Next Year
- ACRS N/A
- NIU $23.71
- P/E Ratio
- ACRS N/A
- NIU N/A
- Revenue Growth
- ACRS N/A
- NIU 50.99
- 52 Week Low
- ACRS $1.05
- NIU $1.66
- 52 Week High
- ACRS $4.24
- NIU $5.67
- Technical
- Relative Strength Index (RSI)
- ACRS 67.71
- NIU 42.54
- Support Level
- ACRS $2.34
- NIU $3.13
- Resistance Level
- ACRS $2.57
- NIU $4.50
- Average True Range (ATR)
- ACRS 0.22
- NIU 0.27
- MACD
- ACRS 0.03
- NIU -0.01
- Stochastic Oscillator
- ACRS 96.18
- NIU 34.67
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About NIU Niu Technologies
Niu Technologies designs, manufactures and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycle, mopeds and bicycle series, including the NQi, MQi, UQi, F series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.